Importantly, CXCR1/2-targeting therapies show promise to capitalize on recent initiatives aiming to increase early screening for autoantibodies to identify patients with a high risk of T1D early (170, 171), when therapies can aim to preserve β cell function and delay or prevent symptomatic T1D onset and reliance on insulin. Here, INS is linked to type 1 diabetes mellitus.